Roche : Invitation to Roche’s Virtual Early Drug Development gRED Event 2020

Basel, 27 January 2020

Invitation to Roche's Virtual Early Drug Development gRED Event 2020

We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Tuesday, February 18, 2020 , highlighting Roche's early drug development with a focus on Genentech Research and Early Development (gRED).

We would like to invite all interested parties to dial in as outlined below:
Tuesday, February 18, 2020
15:30 - 17:00 CET/ 14:30 - 16:00 GMT
9:30 am - 11:00 am EST / 6:30 am - 8:00 am PST

Video webcast and conference call will start with presentations by senior researchers followed by a Q&A session (live access to the speakers).

Agenda:

• Welcome
  Karl Mahler, Head of Investor Relations and Roche Group Planning
• Overview and Introduction to Genentech (gRED)
  Michael Varney, Head of Genentech Research and Early Development
• Non-Oncology Pipeline Overview
  Andy Chan, Senior Vice President, Research Biology for gRED
• Oncology Pipeline Overview
  Stuart Lutzker, Vice President, Oncology Research and ad interim Head of Early Clinical Development for gRED
• Cancer Immunotherapy
  Ira Mellman, Vice President, Cancer Immunology and Immunology for gRED

Access to Video webcast

Please access by clicking on ir.roche.com.

Access to Conference Call (pre-registration required)

You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here.

Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start:

[phone] (Europe & RoW)
[phone] (UK)
[phone] (USA)

A replay of the webcast will be available via ir.roche.com.